MindMed to Present at Upcoming May Medical Conferences

Contributed by: Business Wire

Logo

Tags

Mental Health

Health

Other Health

General Health

Clinical Trials

Pharmaceutical

Biotechnology

Dan Karlin

More Like This

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

MindMed to Present at Upcoming April Medical Conferences

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

MindMed Reports 2023 Financial Results and Business Updates

MindMed Reports First Quarter 2024 Financial Results and Business Updates